Biomarin Pharmaceutical (FRA:BM8) FCF Margin % : 1.98% (As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Biomarin Pharmaceutical's Free Cash Flow for the three months ended in Mar. 2024 was €12 Mil. Biomarin Pharmaceutical's Revenue for the three months ended in Mar. 2024 was €597 Mil. Therefore, Biomarin Pharmaceutical's FCF Margin % for the quarter that ended in Mar. 2024 was 1.98%.

As of today, Biomarin Pharmaceutical's current FCF Yield % is 1.06%.

The historical rank and industry rank for Biomarin Pharmaceutical's FCF Margin % or its related term are showing as below:

FRA:BM8' s FCF Margin % Range Over the Past 10 Years
Min: -50.25 Med: -7.55 Max: 10.04
Current: 6.67

During the past 13 years, the highest FCF Margin % of Biomarin Pharmaceutical was 10.04%. The lowest was -50.25%. And the median was -7.55%.

FRA:BM8's FCF Margin % is ranked better than
84.04% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs FRA:BM8: 6.67

Biomarin Pharmaceutical FCF Margin % Historical Data

The historical data trend for Biomarin Pharmaceutical's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical FCF Margin % Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-6.76

-2.80

10.04

2.12

2.13

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-16.55	7.95	19.31	-1.43	1.98

Competitive Comparison of Biomarin Pharmaceutical's FCF Margin %

For the Biotechnology subindustry, Biomarin Pharmaceutical's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomarin Pharmaceutical's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's FCF Margin % falls into.

Biomarin Pharmaceutical FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Biomarin Pharmaceutical's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	47.362	/	2218.43
	=	2.13 %

Biomarin Pharmaceutical's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	11.837	/	596.926
	=	1.98 %

Biomarin Pharmaceutical FCF Margin % Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (FRA:BM8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (FRA:BM8) Headlines

No Headlines